In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells.
P. aeruginosa forms biofilms in the lungs of individuals with cystic fibrosis (CF); however, there have been no effective model systems for studying biofilm formation in the CF lung. We have developed a tissue culture system for growth of P. aeruginosa biofilms on CF-derived human airway cells that promotes the formation of highly antibiotic-resistant microcolonies, which produce an extracellular polysaccharide matrix and require the known abiotic biofilm formation genes flgK and pilB. Treatment of P. aeruginosa biofilms with tobramycin reduced the virulence of the biofilms both by reducing bacterial numbers and by altering virulence gene expression. We performed microarray analysis of these biofilms on epithelial cells after treatment with tobramycin, and we compared these results with gene expression of (i) tobramycin-treated planktonic P. aeruginosa and (ii) tobramycin-treated P. aeruginosa biofilms on an abiotic surface. Despite the conservation in functions required to form a biofilm, our results show that the responses to tobramycin treatment of biofilms grown on biotic versus abiotic surfaces are different, as exemplified by downregulation of genes involved in Pseudomonas quinolone signal biosynthesis specifically in epithelial cell-grown biofilms versus plastic-grown biofilms. We also identified the gene PA0913, which is upregulated by tobramycin specifically in biofilms grown on CF airway cells and codes for a probable magnesium transporter, MgtE. Mutation of the PA0913 gene increased the bacterial virulence of biofilms on the epithelial cells, consistent with a role for the gene in the suppression of bacterial virulence. Taken together, our data show that analysis of biofilms on airway cells provides new insights into the interaction of these microbial communities with the host.
Anderson
Gregory G
GG
Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
Moreau-Marquis
Sophie
S
Stanton
Bruce A
BA
O'Toole
George A
GA
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017920:Antiporters / Q000235:genetics; D001426:Bacterial Proteins / Q000235:genetics; D018441:Biofilms / Q000187:drug effects*; D002460:Cell Line; D003550:Cystic Fibrosis / Q000201:enzymology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000378:metabolism; D004847:Epithelial Cells / Q000201:enzymology / Q000378:metabolism / Q000382:microbiology*; D006801:Humans; D010088:Oxidoreductases / Q000235:genetics; D040081:Protein Array Analysis; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics / Q000502:physiology*; D014031:Tobramycin / Q000494:pharmacology*; D014158:Transcription, Genetic
D000900:Anti-Bacterial Agents; D017920:Antiporters; D001426:Bacterial Proteins; C088595:FlgK protein, Bacteria; C092192:MgtE protein, bacteria; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D010088:Oxidoreductases; C068255:pilB protein, Bacteria; D014031:Tobramycin